Literature DB >> 29035891

Inhibiting ROS-TFEB-Dependent Autophagy Enhances Salidroside-Induced Apoptosis in Human Chondrosarcoma Cells.

Wei Zeng1,2, Tao Xiao1, Anlie Cai2, Weiliang Cai1, Huanhuan Liu3, Jingling Liu2, Jie Li2, Miduo Tan4, Li Xie5, Ying Liu2, Xiangcheng Yang2, Yi Long2.   

Abstract

BACKGROUND/AIMS: Autophagy modulation has been considered a potential therapeutic strategy for human chondrosarcoma, and a previous study indicated that salidroside exhibits significant anti-carcinogenic activity. However, the ability of salidroside to induce autophagy and its role in human chondrosarcoma cell death remains unclear.
METHODS: We exposed SW1353 cells to different concentrations of salidroside (0.5, 1 and 2 mM) for 24 h. RT-PCR, Western-blotting, Immunocytofluorescence, and Luciferase Reporter Assays were used to evaluate whether salidroside activated the TFEB-dependent autophagy.
RESULTS: We show that salidroside induced significant apoptosis in the human chondrosarcoma cell line SW1353. In addition, we demonstrate that salidroside-induced an autophagic response in SW1353 cells, as evidenced by the upregulation of LC3-II and downregulation of P62. Moreover, pharmacological or genetic blocking of autophagy enhanced salidroside -induced apoptosis, indicating the cytoprotective role of autophagy in salidroside-treated SW1353 cells. Salidroside also induced TFEB (Ser142) dephosphorylation, subsequently to activated TFEB nuclear translocation and increase of TFEB reporter activity, which contributed to lysosomal biogenesis and the expression of autophagy-related genes. Importantly, we found that salidroside triggered the generation of ROS in SW1353 cells. Furthermore, NAC, a ROS scavenger, abrogated the effects of salidroside on TFEB-dependent autophagy.
CONCLUSIONS: These data demonstrate that salidroside increased TFEB-dependent autophagy by activating ROS signaling pathways in human chondrosarcoma cells. These data also suggest that blocking ROS-TFEB-dependent autophagy to enhance the activity of salidroside warrants further attention in treatment of human chondrosarcoma cells.
© 2017 The Author(s). Published by S. Karger AG, Basel.

Entities:  

Keywords:  Apoptosis; Autophagy; Chondrosarcoma; Reactive Oxygen Species; Salidroside; TFEB

Mesh:

Substances:

Year:  2017        PMID: 29035891     DOI: 10.1159/000481971

Source DB:  PubMed          Journal:  Cell Physiol Biochem        ISSN: 1015-8987


  6 in total

Review 1.  Autophagy and Hallmarks of Cancer.

Authors:  Tianzhi Huang; Xiao Song; Yongyong Yang; Xuechao Wan; Angel A Alvarez; Namratha Sastry; Haizhong Feng; Bo Hu; Shi-Yuan Cheng
Journal:  Crit Rev Oncog       Date:  2018

2.  Transcription factor EB (TFEB)-mediated autophagy protects bovine mammary epithelial cells against H2O2-induced oxidative damage in vitro.

Authors:  Xudong Sun; Renxu Chang; Yan Tang; Shengbin Luo; Chunhui Jiang; Hongdou Jia; Qiushi Xu; Zhihao Dong; Yusheng Liang; Juan J Loor; Chuang Xu
Journal:  J Anim Sci Biotechnol       Date:  2021-03-09

3.  CCN6-mediated MMP-9 activation enhances metastatic potential of human chondrosarcoma.

Authors:  Huey-En Tzeng; Chih-Hsin Tang; Sz-Hua Wu; Hsien-Te Chen; Yi-Chin Fong; Yung-Chang Lu; Wei-Cheng Chen; Hsien-Da Huang; Chih-Yang Lin; Shih-Wei Wang
Journal:  Cell Death Dis       Date:  2018-09-20       Impact factor: 8.469

4.  NEO212 induces mitochondrial apoptosis and impairs autophagy flux in ovarian cancer.

Authors:  Xingguo Song; Lisheng Liu; Minghui Chang; Xinran Geng; Xingwu Wang; Weijun Wang; Thomas C Chen; Li Xie; Xianrang Song
Journal:  J Exp Clin Cancer Res       Date:  2019-06-07

Review 5.  Dissecting the mechanism of temozolomide resistance and its association with the regulatory roles of intracellular reactive oxygen species in glioblastoma.

Authors:  Chia-Hung Chien; Wei-Ting Hsueh; Jian-Ying Chuang; Kwang-Yu Chang
Journal:  J Biomed Sci       Date:  2021-03-08       Impact factor: 8.410

Review 6.  Metabolic Pathways and Targets in Chondrosarcoma.

Authors:  Ida Micaily; Megan Roche; Mohammad Y Ibrahim; Ubaldo Martinez-Outschoorn; Atrayee Basu Mallick
Journal:  Front Oncol       Date:  2021-12-06       Impact factor: 6.244

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.